Holen Sie sich die Stockscreener-App
0.2233
24.51%
-0.088
Schlusskurs vom Vortag:
$0.3113
Offen:
$0.26185
24-Stunden-Volumen:
380.87K
Relative Volume:
66.00
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.33M
KGV:
-0.00196
EPS:
-113.7479
Netto-Cashflow:
$-9.12M
1W Leistung:
-24.51%
1M Leistung:
-62.29%
6M Leistung:
-84.44%
1J Leistung:
-93.80%
1-Tages-Spanne:
$0.221
$0.2845
1-Wochen-Bereich:
$0.221
$0.2845
52-Wochen-Spanne:
$0.221
$0.2845
Zyversa Therapeutics Inc Stock (ZVSA) Company Profile
Firmenname
Zyversa Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ZVSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZVSA
Zyversa Therapeutics Inc
|
0.2233 | 0 | 0 | -21.33M | -9.12M | -113.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Zyversa Therapeutics Inc Aktie (ZVSA) Neueste Nachrichten
ZyVersa Therapeutics approved for trading on OTCQB Venture Market By Investing.com - Investing.com India
ZyVersa Therapeutics Stock Approved for OTCQB Listing - TipRanks
Custom watchlist performance reports with ZyVersa Therapeutics Inc.Free Swing Setup With Technical Confirmation - Newser
When is ZyVersa Therapeutics Inc. stock expected to show significant growthMarket-leading growth rates - jammulinksnews.com
Visual analytics tools that track ZyVersa Therapeutics Inc. performanceFree Reliable Alerts for Daily Stock Movers - Newser
Reversal indicators forming on ZyVersa Therapeutics Inc. stock Monthly Long-Term Market Recap and Summary - Newser
What makes ZyVersa Therapeutics Inc. stock price move sharplyDiscover stocks with strong growth potential - jammulinksnews.com
Is it the right time to buy ZyVersa Therapeutics Inc. stockHigh-impact investment strategies - jammulinksnews.com
What institutional investors are buying ZyVersa Therapeutics Inc. stockDouble or triple returns - jammulinksnews.com
Published on: 2025-07-27 20:08:17 - jammulinksnews.com
Is ZyVersa Therapeutics Inc. a growth stock or a value stockUnlock exclusive trading tools and resources - jammulinksnews.com
Key External Factors That Drive ZyVersa Therapeutics Inc. Stock Price MovementsRisk Managed Trading Strategy - Newser
Is ZyVersa Therapeutics Inc. a Top Dividend Stock to Watch in 2025Big Return Stock Tips - Newser
ZyVersa Therapeutics Inc. Stock Analysis and ForecastConsistently high returns - PrintWeekIndia
What analysts say about ZyVersa Therapeutics Inc. stockExceptional profit potential - Autocar Professional
Is ZyVersa Therapeutics Inc. a good long term investmentRapid-fire capital growth - Autocar Professional
What drives ZyVersa Therapeutics Inc. stock priceRapidly growing investment returns - jammulinksnews.com
ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter - GlobeNewswire
ZyVersa secures $12 million in financing to advance kidney disease trials - Investing.com Canada
ZyVersa Therapeutics Updates Shareholders on Key Developments and R&D Milestones in Mid-Year Letter - Nasdaq
ZyVersa Therapeutics Raises $12M to Accelerate Breakthrough Kidney and Inflammatory Disease Treatments - Stock Titan
ZVSA’s Market Whiplash: -93.65% YTD Decline, -52.27% Plunge in 30 Days - investchronicle.com
Why ZyVersa Therapeutics Inc. stock attracts strong analyst attentionFree Best Performing Stock Suggestions - Newser
ZyVersa Therapeutics to be delisted from Nasdaq, trading to move to OTC market - Investing.com India
ZyVersa Therapeutics Faces Nasdaq Delisting, Plans Pink Market Move - TipRanks
ZyVersa Therapeutics to be delisted from Nasdaq, trading to move to OTC market By Investing.com - Investing.com South Africa
How ZyVersa Therapeutics Inc. stock performs during market volatilityWatchlist Winner Update - Newser
ZyVersa Therapeutics (NASDAQ:ZVSA) Rating Increased to Hold at Wall Street Zen - Defense World
ZyVersa Therapeutics (ZVSA) Stock Price, News & Analysis - MarketBeat
ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator?? VAR 200 in A Patient with ApoCII Amyloidosis - MarketScreener
Why Did ZyVersa Therapeutics Plunge 10% Despite Funding Boost? - AInvest
ZyVersa Therapeutics (NASDAQ:ZVSA) Shares Up 17.4% – Time to Buy? - Defense World
ZyVersa Therapeutics Enters Warrant Exercise Agreement - TipRanks
Finanzdaten der Zyversa Therapeutics Inc-Aktie (ZVSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.30%
1.09%
Kapitalisierung:
|
Volumen (24h):